GSK837149A

Cat. No.: HY-117769 Purity: ≥99.0%: Data Sheet
SDS

COA
Handling Instructions Technical Support

Solubility

In Vivo Dissolution Calculator

GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (K_i=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer.

For research use only. We do not sell to patients.

GSK837149A Chemical Structure

CAS No. : 13616-29-0

Size	Price	Stock	Quantity
1 mg	USD 74	In-stock	Estimated Time of Arrival: April 7
5 mg	USD 220	In-stock	Estimated Time of Arrival: April 7
10 mg		Get quote
50 mg		Get quote

Get it by April 11 for select sizes. Order within 13 hrs 2 mins.

or Bulk Inquiry

* Please select Quantity before adding items.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Ki: 30 nM (type I FASN)^[1]

In Vitro

GSK837149A (0.1 nM-0.1 mM) shows an increasing inhibition effect on acetyl-CoA/malonyl-CoA, and acetoacetyl-CoA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

554.60

Formula

C₂₃H₂₂N₈O₅S₂

CAS No.

13616-29-0

Appearance

Solid

Color

White to off-white

SMILES

O=C(NC1=CC=C(C=C1)S(=O)(NC2=NC=CC(C)=N2)=O)NC3=CC=C(C=C3)S(=O)(NC4=NC=CC(C)=N4)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (18.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8031 mL	9.0155 mL	18.0310 mL
5 mM	0.3606 mL	1.8031 mL	3.6062 mL
10 mM	0.1803 mL	0.9016 mL	1.8031 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (1.80 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (1.80 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1 mg/mL (1.80 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, PEG300/PEG400, Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Purity & Documentation

Purity: ≥99.0%

Select Batch:

Data Sheet (271 KB) SDS (392 KB)

COA (245 KB)Elemental Analysis Report (104 KB)

Handling Instructions (2659 KB)

References

[1]. Vázquez MJ, et al. Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the beta-ketoacyl reductase reaction. FEBS J. 2008 Apr;275(7):1556-1567. [Content Brief]

[2]. Singha PK, et al. Evaluation of FASN inhibitors by a versatile toolkit reveals differences in pharmacology between human and rodent FASN preparations and in antiproliferative efficacy in vitro vs. in situ in human cancer cells. Eur J Pharm Sci. 2020 Apr 7;149:105321. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.8031 mL	9.0155 mL	18.0310 mL	45.0775 mL
	5 mM	0.3606 mL	1.8031 mL	3.6062 mL	9.0155 mL
	10 mM	0.1803 mL	0.9016 mL	1.8031 mL	4.5078 mL
	15 mM	0.1202 mL	0.6010 mL	1.2021 mL	3.0052 mL

GSK837149A Related Classifications

Metabolic Disease

Keywords:

GSK837149A13616-29-0Fatty Acid Synthase (FASN)Inhibitorinhibitorinhibit

Your Recently Viewed Products:

GSK837149A

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

GSK837149A

GSK837149A Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

Biological Activity

Purity & Documentation

References

Customer Review

GSK837149A Related Antibodies

Molarity Calculator

Dilution Calculator